Subsidies & Funding

We empower medical innovation

Project Management

We manage research & innovation projects

Business Strategy

We support successful commercialisation

Services

Corona - Funding for R&D

A guide to funding possibilities for biotech and medtech companies in times of Corona crisis.

The Corona outbreak is a healthcare, societal and economic crisis with two faces for medtech and biotech: we are expected to come with solutions at unprecedented rates while ongoing developments are hit hard. Many companies are hence forced to revise their R&D and funding strategies while facing future uncertainties. This guide provides an overview of different support measures taken, enabling you to adapt quickly. The opportunities are organised along the following categories (you find these in the tabs at the top of this page):

This article will be updated regularly – so make sure to check in once in a while or subscribe to our newsletter.

Do you wish to talk to one of our consultants for more information? Please contact us!

This page will give you an overview of acute opportunities for companies working on Corona solutions.

* Europe (Europe-wide, Netherlands, UK)
* USA (NIH, Bill & Melinda Gates foundation)

EUROPE

PRACE

  • PRACE support to mitigate impact of COVID-19. PRACE is welcoming project proposals requesting computing resources to contribute to the mitigation of the impact of the COVID-19 pandemic. This applies, without being exhaustive, to the following topics:

    • Biomolecular research to understand the mechanisms of the virus infection
    • Bioinformatics research to understand mutations, evolution, etc.
    • Bio-simulations to develop therapeutics and/or vaccines
    • Epidemiologic analysis to understand and forecast the spread of the disease
    • Other analyses to understand and mitigate the impact of the pandemic

    Project duration: 3 to 6 months
    Participants:  Researchers from academia, from research institutes, and from commercial organisations (industry) based in Europe are eligible to apply
    Subsidy: about 30 million to 50 million core hours (PRACE facilitates its computing resources, e.g. supercomputers).
    Deadline: open until further notice

InnovFin

  • InnovFin Infectious Diseases is a joint initiative by the European Investment Bank (EIB) and the European Commission under Horizon 2020, providing funding for the development of vaccines, drugs, medical and diagnostic devices, and research infrastructures for combatting infectious diseases. The funding is aimed at projects that have passed the pre-clinical stage and for which clinical validation is needed for further development.

    Deadline: This initiative is continuously open for application.
    Loan amount:  Loan with a size of between €7.5 and €75 million, with a tenor of 7 years. The EIB will finance a maximum of 50% of eligible project costs, thus co-financing is required from the company's own resources.
    Participants: Large pharmaceutical companies, mid-caps or SMEs, research universities, and non-for profit entities from H2020 Member States.
     

EC - ERA Research & Innovation actions

Second wave of COVID19-related grants (H2020-SC1-PHE-CORONAVIRUS-2020-2):

  • Repurposing of manufacturing for vital medical supplies and equipment (H2020-SC1-PHE-CORONAVIRUS-2020-2A): Proposals for innovation actions targeted under this topic should address the re-orientation and repurposing of production capacities to meet the urgent needs of our societies for vital medical supplies and equipment. The scope covers: 1) The repurposing, adaptation and ramp-up of production lines to quickly adjust to new and urgent production needs, notably medical equipment (e.g. personal protective equipment (PPE), ventilators), diagnostic technologies already deployed based on advanced materials and/or biotechnologies, as well as service systems and automated systems of disinfection, 2) Demonstrate flexibility models for the supply chain for the repurposing of production lines and proper risk management in case of disruption of supply chains (or other necessary means for enabling production, such as energy feedstock), 3) Automation technologies that are less dependent on work force present in factories, certification/calibration/accreditation of production lines that have been repurposed or restarted after a shutdown, 4) Qualification of operators/technicians for new/repurposed production lines.
  • Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL) (H2020-SC1-PHE-CORONAVIRUS-2020-2B): Scope: Innovation Actions of one of the following two categories to:

    1) Support solutions that are close-to-market (TRL 7) in one of the COVID-19 areas mentioned below and that have already received, or are about to receive, the CE marking to proceed to large scale testing, piloting and deployment operations in critical healthcare areas (or wherever else is relevant) (type 1);

    2) Support market innovation (from lab-to-fab) for further developing and maturing innovative solutions that have already been validated in lab environments (TRL 6-7 or higher) with the aim to help accelerate developments and achieve conformity assessment (CE marking) (type 2).

  • Behavioural, social and economic impacts of the outbreak response (H2020-SC1-PHE-CORONAVIRUS-2020-2C): Scope: Proposals should focus on lessons learnt: they should i) address how to mitigate social and economic impacts of the outbreak response related to health systems; ii) identify non-intended consequences of epidemic-control decisions; and iii) provide answers to social, including gendered, dynamics of the outbreak and the related public health response. Proposals should analyse the effects and efficiency of these responses (including resilience factors), democratic governance, multi-level cooperation, the critical gaps and the various exit strategies, their underlying methodologies and regional adaptations. Proposals are expected to develop guidelines and best ‘next practices’, and implement interventions to mitigate impacts and boost wellbeing.

  • Pan-European COVID-19 cohorts (H2020-SC1-PHE-CORONAVIRUS-2020-2D): Specific Challenge: The COVID-19 pandemic created an urgent demand for evidence-based innovative and rapid solutions to deal with health and health-related emergencies, to offer the best possible care to patients, and to protect the general population and the frontline health care staff. This expression of interest is to complement research efforts in the fight against the coronavirus, in particular projects resulting from the first H2020 expression of interest, which is currently addressing epidemiology and modelling, diagnostics, treatment, and vaccine. In parallel, Research and Innovation should without delay start analysing the lessons from the present crisis, in particular its impact on health and socio-economic aspects, and propose recommendations for being better prepared in the future if confronted with similar events.

  • Networking of existing EU and international cohorts of relevance to COVID-19 (H2020-SC1-PHE-CORONAVIRUS-2020-2D): Specific Challenge: Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and various factors that might be associated to the perturbation of health. Such existing cohorts might provide key information relevant to COVID-19, including on risk factors, the benefits and risks of healthcare interventions including medicines and on the impact of vaccination. However, the challenge is to be able to identify and extract a sufficiently high number of cases with corresponding high-quality data that can be used across the different cohorts. Consequently, existing cohorts should be brought together in a common effort to standardize data associated to COVID-19 and extract information that will help ensuring optimal prevention, protection and treatment of citizens.

  • EIC Horizon Prize for ‘Early Warning for Epidemics: The challenge is to develop a reliable, cost-effective and scalable early warning system prototype to forecast and monitor vector-borne diseases, which should encompass innovative technological solutions integrating big data derived from different sources (e.g. space-borne, airborne, in-situ and citizen observations) in Earth observation domain, including climate data, vector-related modelling, meteorology, and geo-located information related to vector-borne disease outbreaks and behaviour. These should be interoperable with public health data and other socio-economic data. The solution must be a fully functional prototype system.

    Participants: The contest is open to all legal entities (i.e. natural or legal persons, including international organizations) or groups of legal entities.
    Deadline: The deadline for submitting a proposal is September 1, 2020 at 17:00 CET.
    Budget: indicative budget for this prize is €5 million.

 

NETHERLANDS

Dutch Ministry of Economic Affairs

  • Invest-NL has prioritized climate-related investments in the recent past; they are talking about ways to go off the beaten track.

ZonMW / NWO

  • ZonMw/NWO funding for research to COVID-19 program (In Dutch): The aim of this program is to contribute with €27 million to combating the consequences of the coronavirus (COVID-19) in the short and longer term and to generate new knowledge about prevention, treatment, recovery from this infectious disease and broader social issues.

    The program will focus on the following 3 research pillars:

    1.Predictive diagnostics and treatment - Project ideas closed, full proposal OPEN
    2. Care and prevention, including transmission - Project ideas closed, full proposal OPEN
    3. Social consequences of the corona crisis and measures against it - Project ideas still OPEN

    Deadline: The deadline for project ideas for topics 1 and 2 have been closed, but for topic 3 it is still open 
    Maximum funding amount: €500,000

 

 

UK

UKRI

  • UKRI GCRF/Newton Fund - Agile Response call to address COVID-19 in Low to Middle Income Countries

    This call is funded through the Global Challenges Research Fund and the Newton Fund, which are part of the UK's Official Development Assistance commitment. UKRI will support excellent proposals which seek to address (at least) one of the following:

    - New research or innovation with a clear pathway to impact on policy or practice that has the potential (within the period of the award) to deliver a significant contribution to the understanding of, response to, and recovery from the COVID-19 pandemic in a developing country context.
    - Support the manufacture and/or wide scale adoption of an intervention with significant potential for impact in developing countries.
    - Critical data and resources quickly for future research use.

    Participants: Proposals will be accepted by anyone based in a UK Research Organisation eligible to receive funding from UKRI Research Councils or based in approved Research Organisations overseas. Applicants from low and middle income countries (LMICs) identified on the OECD DAC list of ODA recipients are strongly encouraged to apply to and participate in this call.

Deadline: 31 Dec 2020
Maximum funding amount: Grant size not specified

  • Ideas that address COVID-19: Short-term projects addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak. Maximum project duration 18 months. Focus on one of the followin topics

    •  new research or innovation with a clear impact pathway that has the potential (within the period of the grant) to deliver a significant contribution to the understanding of, and response to, the COVID-19 pandemic and its impacts.
    •  supports the manufacture and/or wide scale adoption of an intervention with significant potential
    •  gathers critical data and resources quickly for future research use

    Participants: UK-based businesses: from pre-start up to new companies to large multi-nationals.
    Deadline: Not specified
    Maximum funding amount: Not specified. Grants will cover 80% of full costs
     

 

US

NIH

  • NIH Research Project Grant (PA-19-056 - Code: R01):  Clinical Trial Not Allowed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

    Maximum project duration: 5 years
    Participants: Non-US entities allowed
    Deadline: 3 deadlines/year
    Maximum funding amount: Budget not limited

 

  • NIBIB Research Project Grant (PA-18-418 - Code: R01): Clinical Trial Required. NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development.

    Maximum project duration: 5 years
    Participants: Non-US entities allowed
    Deadline: 3 deadlines/year
    Maximum funding amount: Budget not limited

 

 

 

  • NIBIB Exploratory/Developmental Research Grant (PAR-18-433 - Code: R21): Clinical Trial Optional. To support exploratory / developmental research projects of interest to the NIBIB. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project.

    Participants: Non-US entities allowed
    Deadline: 3 deadlines/year
    Maximum funding amount: Budget not limited

 

  • NIH Small Research Grant Program (PA-19-052 - Code: R03): Clinical Trial Not Allowed. Pilot or feasibility studies; Secondary analysis of existing data; Small, self-contained research projects; Development of research methodology; and Development of new research technology.

    Maximum project duration: 2 years
    Participants: Non-US entities allowed
    Deadline: 3 deadlines/yea
    Maximum funding amount: $50,000 in direct costs/year
     
  • NIH Exploratory/Developmental Research Grant Program (PA-19-053 - Code: R21) Clinical Trial Not Allowed. Offers support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. 

    Maximum project duration: 2 years
    Participants: Non-US entities allowed
    Deadline: 3 deadlines/year
    Maximum funding amount: $275,000 in direct costs/year

Bill & Melinda Gates Foundation

  •  COVID-19 Therapeutics Accelerator:
    The Bill and Melinda Gates Foundation is joining forces with Wellcome and Mastercard. They have announced (the 10th of March) to invest $125 million to tackle this epidemic. The money will be used to identify potential treatments for COVID-19, accelerate their development, and prepare for the manufacture of millions of doses for use worldwide. The expertise of pharmaceutical companies will be critical to this endeavor, named the COVID-19 Therapeutics Accelerator. 

    Deadline: 31 Dec 2020
     

 

This page will give you an overview of opportunities for non-corona related R&D.

 

KWF

The purpose of the pilot "Infrastructurele initiatieven" by the Dutch Cancer Society (KWF) is to give an impulse to existing or new infrastructural initiatives that support oncological research and to ensure that research findings lead to concrete applications for patients and the general public more often, and more quickly.

Who can apply? Any Dutch non-profit organization can act as the leading institute, and the initiative should have national support. The project leader is not required to hold a PhD.

What to apply for? There is no pre-specified maximum budget per project. High amounts can be applied for if fully justified. Projects are to last between 1 and 5 years. Costs for site visits can be included.

Deadline: For this call, there is a two-stage application process. The deadline for submitting a pre-proposal is June 3, 2020. Full proposals, on invitation only, are due August 26, 2020, at 12:00 CEST.

>> More information

ERC Advanced

ERC Advanced Grants (AdG) are designed to support excellent Principal Investigators which have already established themselves as research leaders with a recognized track record of research achievements. Applicant Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal; in other words, a proposal should not be incremental with respect to your current scientific track-record and the current state of the art, while (maybe in some way contradicting) you should make clear that you have all the skills to perform the proposed research.

Who can apply? Researchers (conducted in a public or private research organization) of any nationality who intend to conduct their research activity in any ERC Member State or Associated Country are eligible to apply.

What to apply for? A subsidy of €2.500.000 for 5 years, plus an optional, additional €1.000.000 for infrastructural investments or for relocation to the EU.

Deadline: August 26

>> More Information

Browse our Funding Database for an overview of non-Corona related calls.

This page will give you an overview of national initiatives to support biotech and medtech companies in acute need.

National initiatives to support companies in acute need

If there is anything you would like to add, feel free to get in touch with us via info@ttopstart.com.